Our findings firmly position RIPOR2 as a promising prognostic biomarker in cervical cancer and demonstrate the effect of viral oncoproteins in downregulating RIPOR2 transcriptional variants. This evidence concerns the gene RIPOR2 and cervical carcinoma.